Evidence map›Paper›PMID 31961326›Full record

ArticleJMIR research protocols2020

Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study.

Rob A A van Kollenburg, Luigi A M J G van Riel, Paul R Bloemen, Jorg R Oddens, Theo M de Reijke, Harrie P Beerlage, Daniel Martijn de Bruin

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rob A A van KollenburgDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0001-9709-5146
Luigi A M J G van RielDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0001-5759-3909
Paul R BloemenDepartment of Biomedical Engineering & Physics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-2845-1378
Jorg R OddensDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-6079-5613
Theo M de ReijkeDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0003-0651-7361
Harrie P BeerlageDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0001-8422-2441
Daniel Martijn de BruinDepartment of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0003-3047-3637
Amsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStandard surgical treatments for lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) use a transurethral approach. Drawbacks are the need for general or spinal anesthesia and complications such as hematuria, strictures, and cloth retention. Therefore, a minimal invasive technique under local anesthesia is desired to improve patient safety. Recently, SoracteLite transperineal laser ablation (TPLA) has been introduced as a novel minimal invasive treatment for BPO. The system used is unique because 4 laser sources are independently available. This 1064-nm diode laser induces coagulative necrosis. Moreover, TPLA is unique because it has a transperineal approach and can be performed under local anesthesia in an outpatient setting.

objectiveThe primary objective of this study is to determine the safety and feasibility of TPLA treatment for men, who are fit for standard surgery, with LUTS due to BPO. The secondary objectives are to determine functional outcomes by flowmetry and patient-reported outcome measures (PROMs), side effects, and tissue changes observed on imaging.

methodsThis study is a prospective, single center, interventional pilot study IDEAL framework stage 2a and will include 20 patients. Eligible patients are men ≥40 years of age, with a prostate volume of 30 to 120 cc, have urodynamically proven bladder outlet obstruction, and have a peak urinary flow of 5 to 15 mL per second. All patients will undergo TPLA of their prostate under local anesthesia by using the EchoLaser system. Depending on the prostate volume, 2 to 4 laser fibers will be placed bilaterally into the prostate. Patient follow-up consists of uroflowmetry, PROMs, and imaging by using contrast-enhanced ultrasound. Total follow-up is 12 months following treatment.

resultsPresently, recruitment of patients is ongoing. Publication of first results is expected by early 2020.

conclusionsTPLA offers the potential to be a novel minimal invasive technique for treatment of LUTS due to BPO in men fit for standard desobstruction. This study will evaluate the safety and feasibility of TPLA and report on functional outcomes and tissue changes observed on imaging following TPLA treatment. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15687.

Indexed as

laser therapylower urinary tract symptomsprostatic hyperplasiatransperineal laser ablation

Identifiers

PMID31961326
PMCPMC7001043
OpenAlexW2973573548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.